Fosfluridine tidoxil

Drug Profile

Fosfluridine tidoxil

Alternative Names: Fosfluridine; HDP 99.0006; HDP 990006

Latest Information Update: 19 Apr 2011

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Heidelberg Pharma
  • Class Antineoplastics; Pyrimidine nucleosides
  • Mechanism of Action Thymidylate synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Suspended Actinic keratosis; Breast cancer; Colorectal cancer

Most Recent Events

  • 28 Feb 2011 Heidelberg Pharma has been acquired by Wilex
  • 15 Nov 2010 Suspended - Phase-II for Actinic keratosis in Germany (PO) before November 2010
  • 15 Nov 2010 Suspended - Phase-II for Breast cancer in Germany (PO) before November 2010
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top